{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T15:35:04Z","timestamp":1791300904704,"version":"4.1.0"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2014,3,28]],"date-time":"2014-03-28T00:00:00Z","timestamp":1395964800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"published-print":{"date-parts":[[2014,6]]},"DOI":"10.1007\/s00262-014-1540-0","type":"journal-article","created":{"date-parts":[[2014,3,27]],"date-time":"2014-03-27T10:27:08Z","timestamp":1395916028000},"page":"601-613","source":"Crossref","is-referenced-by-count":81,"title":["Complete regression and systemic protective immune responses obtained in B16 melanomas after treatment with LTX-315"],"prefix":"10.1007","volume":"63","author":[{"given":"Ketil Andr\u00e9","family":"Camilio","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerd","family":"Berge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chandra Sekhar","family":"Ravuri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00d8ystein","family":"Rekdal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baldur","family":"Sveinbj\u00f8rnsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,3,28]]},"reference":[{"key":"1540_CR1","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.det.2012.04.001","volume":"30","author":"EG Little","year":"2012","unstructured":"Little EG, Eide MJ (2012) Update on the current state of melanoma incidence. Dermatol Clin 30:355\u2013361. doi: 10.1016\/j.det.2012.04.001","journal-title":"Dermatol Clin"},{"key":"1540_CR2","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1345\/aph.18190","volume":"33","author":"E Duran Garcia","year":"1999","unstructured":"Duran Garcia E, Santolaya R, Requena T (1999) Treatment of malignant melanoma. Ann Pharmacother 33:730\u2013738. doi: 10.1345\/aph.18190","journal-title":"Ann Pharmacother"},{"key":"1540_CR3","doi-asserted-by":"crossref","first-page":"229","DOI":"10.3322\/canjclin.15.5.229","volume":"15","author":"G McNeer","year":"1965","unstructured":"McNeer G, Das Gupta T (1965) Treatment of malignant melanoma. CA Cancer J Clin 15:229\u2013231. doi: 10.3322\/canjclin.15.5.229","journal-title":"CA Cancer J Clin"},{"key":"1540_CR4","doi-asserted-by":"crossref","first-page":"3635","DOI":"10.1200\/JCO.2001.19.16.3635","volume":"19","author":"CM Balch","year":"2001","unstructured":"Balch CM, Buzaid AC, Soong SJ, Atkins MB, Cascinelli N et al (2001) Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol 19:3635\u20133648","journal-title":"J Clin Oncol"},{"key":"1540_CR5","doi-asserted-by":"crossref","first-page":"2150","DOI":"10.1016\/j.ejca.2011.06.052","volume":"47","author":"AM Eggermont","year":"2011","unstructured":"Eggermont AM, Robert C (2011) New drugs in melanoma: it\u2019s a whole new world. Eur J Cancer 47:2150\u20132157. doi: 10.1016\/j.ejca.2011.06.052","journal-title":"Eur J Cancer"},{"key":"1540_CR6","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/s00403-012-1223-7","volume":"304","author":"F Spagnolo","year":"2012","unstructured":"Spagnolo F, Queirolo P (2012) Upcoming strategies for the treatment of metastatic melanoma. Arch Dermatol Res 304:177\u2013184. doi: 10.1007\/s00403-012-1223-7","journal-title":"Arch Dermatol Res"},{"key":"1540_CR7","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1038\/415389a","volume":"415","author":"M Zasloff","year":"2002","unstructured":"Zasloff M (2002) Antimicrobial peptides of multicellular organisms. Nature 415:389\u2013395. doi: 10.1038\/415389a","journal-title":"Nature"},{"key":"1540_CR8","doi-asserted-by":"crossref","first-page":"143","DOI":"10.3109\/07388551.2011.594423","volume":"32","author":"M Pasupuleti","year":"2012","unstructured":"Pasupuleti M, Schmidtchen A, Malmsten M (2012) Antimicrobial peptides: key components of the innate immune system. Crit Rev Biotechnol 32:143\u2013171. doi: 10.3109\/07388551.2011.594423","journal-title":"Crit Rev Biotechnol"},{"key":"1540_CR9","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.bbamem.2007.11.008","volume":"1778","author":"DW Hoskin","year":"2008","unstructured":"Hoskin DW, Ramamoorthy A (2008) Studies on anticancer activities of antimicrobial peptides. Biochim Biophys Acta 1778:357\u2013375. doi: 10.1016\/j.bbamem.2007.11.008","journal-title":"Biochim Biophys Acta"},{"key":"1540_CR10","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1517\/13543784.15.8.933","volume":"15","author":"JS Mader","year":"2006","unstructured":"Mader JS, Hoskin DW (2006) Cationic antimicrobial peptides as novel cytotoxic agents for cancer treatment. Expert Opin Investig Drugs 15:933\u2013946. doi: 10.1517\/13543784.15.8.933","journal-title":"Expert Opin Investig Drugs"},{"key":"1540_CR11","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.ejphar.2009.08.043","volume":"625","author":"F Schweizer","year":"2009","unstructured":"Schweizer F (2009) Cationic amphiphilic peptides with cancer-selective toxicity. Eur J Pharmacol 625:190\u2013194. doi: 10.1016\/j.ejphar.2009.08.043","journal-title":"Eur J Pharmacol"},{"key":"1540_CR12","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1016\/j.chemphyslip.2011.09.004","volume":"164","author":"S Riedl","year":"2011","unstructured":"Riedl S, Zweytick D, Lohner K (2011) Membrane-active host defense peptides\u2014challenges and perspectives for the development of novel anticancer drugs. Chem Phys Lipids 164:766\u2013781. doi: 10.1016\/j.chemphyslip.2011.09.004","journal-title":"Chem Phys Lipids"},{"key":"1540_CR13","first-page":"3062","volume":"51","author":"T Utsugi","year":"1991","unstructured":"Utsugi T, Schroit AJ, Connor J, Bucana CD, Fidler IJ (1991) Elevated expression of phosphatidylserine in the outer membrane leaflet of human tumor cells and recognition by activated human blood monocytes. Cancer Res 51:3062\u20133066","journal-title":"Cancer Res"},{"key":"1540_CR14","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/0009-8981(88)90184-2","volume":"176","author":"E Marth","year":"1988","unstructured":"Marth E, Flaschka G, Stiegler S, Mose JR (1988) Sialic-acid as a marker for differentiation between benign and malignant intracranial tumors. Clin Chim Acta 176:251\u2013257. doi: 10.1016\/0009-8981(88)90184-2","journal-title":"Clin Chim Acta"},{"key":"1540_CR15","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1186\/1471-2407-11-116","volume":"11","author":"B Fadnes","year":"2011","unstructured":"Fadnes B, Uhlin-Hansen L, Lindin I, Rekdal O (2011) Small lytic peptides escape the inhibitory effect of heparan sulfate on the surface of cancer cells. BMC Cancer 11:116\u2013126. doi: 10.1186\/1471-2407-11-116","journal-title":"BMC Cancer"},{"key":"1540_CR16","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1172\/JCI4105","volume":"102","author":"J Kleeff","year":"1998","unstructured":"Kleeff J, Ishiwata T, Kumbasar A, Friess H, Buchler MW et al (1998) The cell-surface heparan sulfate proteoglycan glypican-1 regulates growth factor action in pancreatic carcinoma cells and is overexpressed in human pancreatic cancer. J Clin Invest 102:1662\u20131673. doi: 10.1172\/JCI4105","journal-title":"J Clin Invest"},{"key":"1540_CR17","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/S0940-2993(99)80074-8","volume":"51","author":"K Koz\u0142owska","year":"1999","unstructured":"Koz\u0142owska K, Nowak J, Kwiatkowski B, Cichorek M (1999) ESR study of plasmatic membrane of the transplantable melanoma cells in relation to their biological properties. Exp Toxicol Pathol 51:89\u201392. doi: 10.1016\/s0940-2993(99)80074-8","journal-title":"Exp Toxicol Pathol"},{"key":"1540_CR18","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/S0304-3835(99)00044-0","volume":"139","author":"M Sok","year":"1999","unstructured":"Sok M, Sentjurc M, Schara M (1999) Membrane fluidity characteristics of human lung cancer. Cancer Lett 139:215\u2013220. doi: 10.1016\/s0304-3835(99)00044-0","journal-title":"Cancer Lett"},{"key":"1540_CR19","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1111\/j.1365-2303.1995.tb00469.x","volume":"6","author":"J Chaudhary","year":"1995","unstructured":"Chaudhary J, Munshi M (1995) Scanning electron microscopic analysis of breast aspirates. Cytopathology 6:162\u2013167. doi: 10.1111\/j.1365-2303.1995.tb00469.x","journal-title":"Cytopathology"},{"key":"1540_CR20","first-page":"101","volume":"3","author":"W Domagala","year":"1980","unstructured":"Domagala W, Koss L (1980) Surface configuration of human tumor cells obtained by fine needle aspiration biopsy. Scan Electron Microsc 3:101\u2013108","journal-title":"Scan Electron Microsc"},{"key":"1540_CR21","first-page":"151","volume":"15","author":"SA Johnstone","year":"2000","unstructured":"Johnstone SA, Gelmon K, Mayer LD, Hancock RE, Bally MB (2000) In vitro characterization of the anticancer activity of membrane-active cationic peptides. I. Peptide-mediated cytotoxicity and peptide-enhanced cytotoxic activity of doxorubicin against wild-type and p-glycoprotein over-expressing tumor cell lines. Anticancer Drug Des 15:151\u2013160","journal-title":"Anticancer Drug Des"},{"key":"1540_CR22","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/S0196-9781(03)00194-3","volume":"24","author":"S Kim","year":"2003","unstructured":"Kim S, Kim SS, Bang YJ, Kim SJ, Lee BJ (2003) In vitro activities of native and designed peptide antibiotics against drug sensitive and resistant tumor cell lines. Peptides 24:945\u2013953. doi: 10.1016\/s0196-9781(03)00194-3","journal-title":"Peptides"},{"key":"1540_CR23","first-page":"2703","volume":"22","author":"LT Eliassen","year":"2002","unstructured":"Eliassen LT, Berge G, Sveinbjornsson B, Svendsen JS, Vorland LH et al (2002) Evidence for a direct antitumor mechanism of action of bovine lactoferricin. Anticancer Res 22:2703\u20132710","journal-title":"Anticancer Res"},{"key":"1540_CR24","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1002\/ijc.21886","volume":"119","author":"LT Eliassen","year":"2006","unstructured":"Eliassen LT, Berge G, Leknessund A, Wikman M, Lindin I et al (2006) The antimicrobial peptide, lactoferricin B, is cytotoxic to neuroblastoma cells in vitro and inhibits xenograft growth in vivo. Int J Cancer 119:493\u2013500. doi: 10.1002\/ijc.21886","journal-title":"Int J Cancer"},{"key":"1540_CR25","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1158\/1535-7163.MCT-04-0077","volume":"4","author":"JS Mader","year":"2005","unstructured":"Mader JS, Salsman J, Conrad DM, Hoskin DW (2005) Bovine lactoferricin selectively induces apoptosis in human leukemia and carcinoma cell lines. Mol Cancer Ther 4:612\u2013624. doi: 10.1158\/1535-7163.MCT-04-0077","journal-title":"Mol Cancer Ther"},{"key":"1540_CR26","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1006\/bbrc.1997.7199","volume":"237","author":"YC Yoo","year":"1997","unstructured":"Yoo YC, Watanabe R, Koike Y, Mitobe M, Shimazaki K et al (1997) Apoptosis in human leukemic cells induced by lactoferricin, a bovine milk protein-derived peptide: involvement of reactive oxygen species. Biochem Biophys Res Commun 237:624\u2013628. doi: 10.1006\/bbrc.1997.7199","journal-title":"Biochem Biophys Res Commun"},{"key":"1540_CR27","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1111\/j.1349-7006.1997.tb00364.x","volume":"88","author":"YC Yoo","year":"1997","unstructured":"Yoo YC, Watanabe S, Watanabe R, Hata K, Shimazaki K et al (1997) Bovine lactoferrin and lactoferricin, a peptide derived from bovine lactoferrin, inhibit tumor metastasis in mice. Jpn J Cancer Res 88:184\u2013190","journal-title":"Jpn J Cancer Res"},{"key":"1540_CR28","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1007\/s00262-010-0857-6","volume":"59","author":"G Berge","year":"2010","unstructured":"Berge G, Eliassen LT, Camilio KA, Bartnes K, Sveinbjornsson B et al (2010) Therapeutic vaccination against a murine lymphoma by intratumoral injection of a cationic anticancer peptide. Cancer Immunol Immunother 59:1285\u20131294. doi: 10.1007\/s00262-010-0857-6","journal-title":"Cancer Immunol Immunother"},{"key":"1540_CR29","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1002\/psc.472","volume":"9","author":"LT Eliassen","year":"2003","unstructured":"Eliassen LT, Haug BE, Berge G, Rekdal O (2003) Enhanced antitumour activity of 15-residue bovine lactoferricin derivatives containing bulky aromatic amino acids and lipophilic N-terminal modifications. J Pept Sci 9:510\u2013517. doi: 10.1002\/psc.472","journal-title":"J Pept Sci"},{"key":"1540_CR30","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1002\/psc.457","volume":"9","author":"N Yang","year":"2003","unstructured":"Yang N, Lejon T, Rekdal O (2003) Antitumour activity and specificity as a function of substitutions in the lipophilic sector of helical lactoferrin-derived peptide. J Pept Sci 9:300\u2013311. doi: 10.1002\/psc.457","journal-title":"J Pept Sci"},{"key":"1540_CR31","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1034\/j.1399-3011.2002.21008.x","volume":"60","author":"N Yang","year":"2002","unstructured":"Yang N, Stensen W, Svendsen JS, Rekdal O (2002) Enhanced antitumor activity and selectivity of lactoferrin-derived peptides. J Pept Res 60:187\u2013197. doi: 10.1034\/j.1399-3011.2002.21008.x","journal-title":"J Pept Res"},{"key":"1540_CR32","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1002\/psc.470","volume":"10","author":"N Yang","year":"2004","unstructured":"Yang N, Strom MB, Mekonnen SM, Svendsen JS, Rekdal O (2004) The effects of shortening lactoferrin derived peptides against tumour cells, bacteria and normal human cells. J Pept Sci 10:37\u201346. doi: 10.1002\/psc.470","journal-title":"J Pept Sci"},{"key":"1540_CR33","doi-asserted-by":"crossref","first-page":"2787","DOI":"10.1093\/bioinformatics\/bti408","volume":"21","author":"TZ Sen","year":"2005","unstructured":"Sen TZ, Jernigan RL, Garnier J, Kloczkowski A (2005) GOR V server for protein secondary structure prediction. Bioinformatics 21:2787\u20132788. doi: 10.1093\/bioinformatics\/bti408","journal-title":"Bioinformatics"},{"key":"1540_CR34","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/0022-1759(83)90303-4","volume":"65","author":"T Mosmann","year":"1983","unstructured":"Mosmann T (1983) Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 65:55\u201363","journal-title":"J Immunol Methods"},{"key":"1540_CR35","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1006\/meth.2001.1262","volume":"25","author":"KJ Livak","year":"2001","unstructured":"Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2\u2212\u0394\u0394CT method. Methods 25:402\u2013408. doi: 10.1006\/meth.2001.1262","journal-title":"Methods"},{"key":"1540_CR36","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1126\/science.142.3595.1085","volume":"142","author":"HI Zeya","year":"1963","unstructured":"Zeya HI, Spitznagel JK (1963) Antibacterial and enzymic basic proteins from leukocyte lysosomes: separation and identification. Science 142:1085\u20131087. doi: 10.1126\/science.142.3595.1085","journal-title":"Science"},{"key":"1540_CR37","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1128\/JB.91.2.750-754.1966","volume":"91","author":"HI Zeya","year":"1966","unstructured":"Zeya HI, Spitznagel JK (1966) Cationic proteins of polymorphonuclear leukocyte lysosomes I. Resolution of antibacterial and enzymatic activities. J Bacteriol 91:750\u2013754","journal-title":"J Bacteriol"},{"key":"1540_CR38","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1517\/13543784.2011.602064","volume":"20","author":"A Pereira","year":"2011","unstructured":"Pereira A, Kerkis A, Hayashi MA, Pereira AS, Silva FS et al (2011) Crotamine toxicity and efficacy in mouse models of melanoma. Expert Opin Investig Drugs 20:1189\u20131200. doi: 10.1517\/13543784.2011.602064","journal-title":"Expert Opin Investig Drugs"},{"key":"1540_CR39","first-page":"1","volume-title":"B16 as a mouse model for human melanoma. Current PROTOCOLS IN IMMUNOLOGY","author":"WW Overwijk","year":"2001","unstructured":"Overwijk WW, Restifo NP (2001) B16 as a mouse model for human melanoma. Current PROTOCOLS IN IMMUNOLOGY. Wiley, New York, pp 1\u201332"},{"key":"1540_CR40","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.tripleo.2003.12.016","volume":"97","author":"A Barasch","year":"2004","unstructured":"Barasch A, Epstein JB, Foong WC, Clayman L (2004) Intralesional chemotherapy for head and neck carcinoma: a review of the literature. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 97:307\u2013311. doi: 10.1016\/S1079210403007236","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol Endod"},{"key":"1540_CR41","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1007\/BF02667099","volume":"45","author":"DG Cornwell","year":"1968","unstructured":"Cornwell DG, Heikkila RE, Bar RS, Biagi GL (1968) Red blood cell lipids and the plasma membrane. J Am Oil Chem Soc 45:297\u2013304. doi: 10.1007\/BF02667099","journal-title":"J Am Oil Chem Soc"},{"key":"1540_CR42","first-page":"1629","volume":"5","author":"CD Britten","year":"1999","unstructured":"Britten CD, Rowinsky EK, Baker SD, Agarwala SS, Eckardt JR et al (1999) A phase I and pharmacokinetic study of temozolomide and cisplatin in patients with advanced solid malignancies. Clin Cancer Res 5:1629\u20131637","journal-title":"Clin Cancer Res"},{"key":"1540_CR43","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1038\/bjc.1994.165","volume":"69","author":"SM Lee","year":"1994","unstructured":"Lee SM, Margison GP, Thatcher N, O\u2019Connor PJ, Cooper DP (1994) Formation and loss of O6-methyldeoxyguanosine in human leucocyte DNA following sequential DTIC and fotemustine chemotherapy. Br J Cancer 69:853\u2013857","journal-title":"Br J Cancer"},{"key":"1540_CR44","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1517\/14656566.4.12.2205","volume":"4","author":"MB Lens","year":"2003","unstructured":"Lens MB, Eisen TG (2003) Systemic chemotherapy in the treatment of malignant melanoma. Expert Opin Pharmacother 4:2205\u20132211. doi: 10.1517\/14656566.4.12.2205","journal-title":"Expert Opin Pharmacother"},{"key":"1540_CR45","doi-asserted-by":"crossref","first-page":"2711","DOI":"10.1172\/JCI62423","volume":"122","author":"JK Chan","year":"2012","unstructured":"Chan JK, Roth J, Oppenheim JJ, Tracey KJ, Vogl T et al (2012) Alarmins: awaiting a clinical response. J Clin Invest 122:2711\u20132719. doi: 10.1172\/JCI62423","journal-title":"J Clin Invest"},{"key":"1540_CR46","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1089\/ars.2012.5143","volume":"20","author":"DS Pisetsky","year":"2014","unstructured":"Pisetsky DS (2014) The translocation of nuclear molecules during inflammation and cell death. Antioxid Redox Signal 20:1117\u20131125. doi: 10.1089\/ars.2012.5143","journal-title":"Antioxid Redox Signal"},{"key":"1540_CR47","doi-asserted-by":"crossref","first-page":"2652","DOI":"10.1182\/blood-2002-05-1300","volume":"101","author":"C Fiuza","year":"2003","unstructured":"Fiuza C, Bustin M, Talwar S, Tropea M, Gerstenberger E et al (2003) Inflammation-promoting activity of HMGB1 on human microvascular endothelial cells. Blood 101:2652\u20132660. doi: 10.1182\/blood-2002-05-1300","journal-title":"Blood"},{"key":"1540_CR48","doi-asserted-by":"crossref","first-page":"307","DOI":"10.4049\/jimmunol.173.1.307","volume":"173","author":"D Messmer","year":"2004","unstructured":"Messmer D, Yang H, Telusma G, Knoll F, Li J et al (2004) High mobility group box protein 1: an endogenous signal for dendritic cell maturation and Th1 polarization. J Immunol 173:307\u2013313","journal-title":"J Immunol"},{"key":"1540_CR49","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.molimm.2004.07.023","volume":"42","author":"RA DeMarco","year":"2005","unstructured":"DeMarco RA, Fink MP, Lotze MT (2005) Monocytes promote natural killer cell interferon gamma production in response to the endogenous danger signal HMGB1. Mol Immunol 42:433\u2013444. doi: 10.1016\/j.molimm.2004.07.023","journal-title":"Mol Immunol"},{"key":"1540_CR50","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1146\/annurev.immunol.021908.132612","volume":"27","author":"CA Dinarello","year":"2009","unstructured":"Dinarello CA (2009) Immunological and inflammatory functions of the interleukin-1 family. Annu Rev Immunol 27:519\u2013550. doi: 10.1146\/annurev.immunol.021908.132612","journal-title":"Annu Rev Immunol"},{"key":"1540_CR51","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1046\/j.1365-2567.2001.01337.x","volume":"104","author":"S Nakae","year":"2001","unstructured":"Nakae S, Asano M, Horai R, Iwakura Y (2001) Interleukin-1\u03b2, but not interleukin-1\u03b1, is required for T-cell-dependent antibody production. Immunology 104:402\u2013409. doi: 10.1046\/j.1365-2567.2001.01337.x","journal-title":"Immunology"},{"key":"1540_CR52","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1038\/nature04753","volume":"441","author":"E Bettelli","year":"2006","unstructured":"Bettelli E, Carrier Y, Gao W, Korn T, Strom TB et al (2006) Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 441:235\u2013238. doi: 10.1038\/nature04753","journal-title":"Nature"},{"key":"1540_CR53","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.toxicon.2004.10.005","volume":"45","author":"F Chaves","year":"2005","unstructured":"Chaves F, Teixeira CF, Gutierrez JM (2005) Role of TNF-\u03b1, IL-1\u03b2 and IL-6 in the local tissue damage induced by Bothrops asper snake venom: an experimental assessment in mice. Toxicon 45:171\u2013178. doi: 10.1016\/j.toxicon.2004.10.005","journal-title":"Toxicon"},{"key":"1540_CR54","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/s00109-001-0307-1","volume":"80","author":"F Biet","year":"2002","unstructured":"Biet F, Locht C, Kremer L (2002) Immunoregulatory functions of interleukin 18 and its role in defense against bacterial pathogens. J Mol Med (Berl) 80:147\u2013162. doi: 10.1007\/s00109-001-0307-1","journal-title":"J Mol Med (Berl)"},{"key":"1540_CR55","doi-asserted-by":"crossref","first-page":"7014","DOI":"10.4049\/jimmunol.166.12.7014","volume":"166","author":"T Hoshino","year":"2001","unstructured":"Hoshino T, Kawase Y, Okamoto M, Yokota K, Yoshino K et al (2001) Cutting edge: IL-18-transgenic mice: in vivo evidence of a broad role for IL-18 in modulating immune function. J Immunol 166:7014\u20137018","journal-title":"J Immunol"},{"key":"1540_CR56","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S1359-6101(00)00015-0","volume":"12","author":"K Nakanishi","year":"2001","unstructured":"Nakanishi K, Yoshimoto T, Tsutsui H, Okamura H (2001) Interleukin-18 is a unique cytokine that stimulates both Th1 and Th2 responses depending on its cytokine milieu. Cytokine Growth Factor Rev 12:53\u201372. doi: 10.1016\/S1359-6101(00)00015-0","journal-title":"Cytokine Growth Factor Rev"},{"key":"1540_CR57","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1038\/378088a0","volume":"378","author":"H Okamura","year":"1995","unstructured":"Okamura H, Tsutsui H, Komatsu T, Yutsudo M, Hakura A et al (1995) Cloning of a new cytokine that induces IFN-\u03b3 production by T-Cells. Nature 378:88\u201391. doi: 10.1038\/378088a0","journal-title":"Nature"},{"key":"1540_CR58","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/0092-8674(86)90341-7","volume":"46","author":"G Shaw","year":"1986","unstructured":"Shaw G, Kamen R (1986) A conserved AU sequence from the 3\u2032 untranslated region of GM-CSF mRNA mediates selective mRNA degradation. Cell 46:659\u2013667. doi: 10.1016\/0092-8674(86)90341-7","journal-title":"Cell"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00262-014-1540-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-014-1540-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-014-1540-0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,16]],"date-time":"2020-08-16T22:22:27Z","timestamp":1597616547000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00262-014-1540-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,3,28]]},"references-count":58,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2014,6]]}},"alternative-id":["1540"],"URL":"https:\/\/doi.org\/10.1007\/s00262-014-1540-0","relation":{},"ISSN":["0340-7004","1432-0851"],"issn-type":[{"value":"0340-7004","type":"print"},{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,3,28]]}}}